LGND Stock Analysis: Buy, Sell, or Hold?
LGND - Ligand Pharmaceuticals Inc.
$292.04
4.50 (1.56%)
▲
5d:
-1.84%
30d:
-8.61%
90d:
+28.4%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When LGND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
🚀 STRONG BUY: LGND shows excellent value with unusually cheap options (IV 14th percentile) and market pricing in only 2.5% annual growth despite strong fundamentals. High conviction opportunity.
🚀 STRONG BUY: LGND shows excellent value with unusually cheap options (IV 14th percentile) and market pricing in only 2.5% annual growth despite strong fundamentals. High conviction opportunity.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$520.60
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$323.25
9.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LGND is currently trading at $292.04, which is considered oversold relative to its 30-day fair value range of $294.68 to $315.26. The stock's valuation (Forward PE: 24.3) is in line with its historical norms (22.6). At these levels, the market is pricing in 2.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is currently testing key support at $283.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $323.30 (+12.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is currently testing key support at $283.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $323.30 (+12.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$294.68 -
$315.26
Company Quality Score
57/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
82.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 14th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($323.30)
- NEUTRAL: Market pricing in 2.5% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$294.68 -
$315.26
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$20.82
(7.1%)
Support & Resistance Levels
Support Level
$283.77
Resistance Level
$308.56
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.31
Wall Street Target
$323.30
(+12.4%)
Revenue Growth (YoY)
14.1%
Earnings Growth (YoY)
103.2%
Profit Margin
56.0%
Valuation Premium vs History
+2.5% premium
PE vs Historical
24.3 vs 22.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.5%
(market-implied from PE analysis)
1-Year Target
$294.73
(+3%)
2-Year Target
$302.10
(+5%)
3-Year Target
$309.65
(+8%)
3-Yr Target (if PE normalizes)
(PE: 24→23)
PE COMPRESSION
$287.89
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.3, Growth: 28.8%)
$614.33
(+114%)
Base:
(SPY PE: 20.7, Growth: 28.8%)
$523.91
(+82%)
Bear:
(PE: 17.6, Growth: 28.8%)
$445.32
(+55%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 37.60 | Current EPS (TTM): $7.88
Bull Case
$489.25
(+68%)
Analyst growth 50.1%, PE expands to 41.4
Base Case
$444.77
(+52%)
Market implied 50.1%, PE stable at 37.6
Bear Case
$201.48
(-31%)
Severe decline -20.0%, PE contracts to 32.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 04, 2026 4:06 AM ET
Data refreshes hourly during market hours. Next update: 5:06 AM
Data refreshes hourly during market hours. Next update: 5:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGND showing a specific setup today?
Insider Activity (6 Months)
1
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
John W Kozarich
SELL
467 shares
2026-04-01
Andrew Reardon
SELL
5000 shares
2026-04-01
Stephen L Sabba
SELL
1000 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
Advanced LGND Option Strategies
Professional options setups generated by AI based on today's LGND price and gamma walls.
